Alexandra Kollara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5643823/publications.pdf

Version: 2024-02-01

933447 940533 16 293 10 16 citations h-index g-index papers 16 16 16 447 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Research and Treatment, 2001, 67, 245-253.	2.5	40
2	Functional interaction of nuclear receptor coactivator 4 with aryl hydrocarbon receptor. Biochemical and Biophysical Research Communications, 2006, 346, 526-534.	2.1	40
3	Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity. Cellular and Molecular Life Sciences, 2012, 69, 3895-3909.	5.4	30
4	Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Lowversus High-Volume Ascites. BioMed Research International, 2014, 2014, 1-9.	1.9	27
5	VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. British Journal of Cancer, 2017, 116, 1065-1076.	6.4	26
6	Four and a half LIM domain 2 alters the impact of aryl hydrocarbon receptor on androgen receptor transcriptional activity. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 51-58.	2.5	25
7	Variable Expression of Nuclear Receptor Coactivator 4 (NcoA4) During Mouse Embryonic Development. Journal of Histochemistry and Cytochemistry, 2010, 58, 595-609.	2.5	20
8	Human ortholog of <i>Drosophila</i> Melted impedes SMAD2 release from TGF- \hat{l}^2 receptor I to inhibit TGF- \hat{l}^2 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3000-9.	7.1	20
9	Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2003, 84, 493-502.	2.5	15
10	Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. International Journal of Gynecology and Obstetrics, 2018, 143, 325-332.	2.3	11
11	Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2. International Journal of Biochemistry and Cell Biology, 2009, 41, 1182-1188.	2.8	10
12	Glucocorticoid-Induced Reversal of Interleukin- $\hat{1}^2$ -Stimulated Inflammatory Gene Expression in Human Oviductal Cells. PLoS ONE, 2014, 9, e97997.	2.5	9
13	Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model. Journal of Ovarian Research, 2018, 11, 56.	3.0	8
14	BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells. Neoplasia, 2018, 20, 697-709.	5.3	8
15	Dynamic Distribution of Nuclear Coactivator 4 during Mitosis: Association with Mitotic Apparatus and Midbodies. PLoS ONE, 2011, 6, e22257.	2.5	3
16	A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin. Journal of Ovarian Research, 2021, 14, 157.	3.0	1